BioRestorative Therapies’ (BRTX) “Buy” Rating Reiterated at Roth Mkm

Roth Mkm reissued their buy rating on shares of BioRestorative Therapies (NASDAQ:BRTX) in a report issued on Wednesday, Benzinga reports. The brokerage currently has a $15.00 price objective on the stock.

BioRestorative Therapies Stock Down 5.1 %

Shares of BRTX opened at $1.85 on Wednesday. The stock has a market capitalization of $12.52 million, a P/E ratio of -0.80 and a beta of 61.71. The firm has a fifty day simple moving average of $1.34 and a two-hundred day simple moving average of $1.51. BioRestorative Therapies has a twelve month low of $1.03 and a twelve month high of $7.13.

BioRestorative Therapies (NASDAQ:BRTX) last announced its quarterly earnings results on Tuesday, June 11th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.02). The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.03 million. BioRestorative Therapies had a negative net margin of 7,303.33% and a negative return on equity of 96.09%. Sell-side analysts expect that BioRestorative Therapies will post -1.96 EPS for the current fiscal year.

Institutional Investors Weigh In On BioRestorative Therapies

A hedge fund recently bought a new stake in BioRestorative Therapies stock. StoneX Group Inc. purchased a new stake in shares of BioRestorative Therapies, Inc. (NASDAQ:BRTX) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 34,850 shares of the company’s stock, valued at approximately $48,000. StoneX Group Inc. owned 0.51% of BioRestorative Therapies as of its most recent SEC filing. Hedge funds and other institutional investors own 69.38% of the company’s stock.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.